Application Nr Approved Date Route Status External Links
ANDA078106 None Oral None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

1 Indications And Usage Levetiracetam Is Indicated For Adjunctive Therapy In The Treatment Of: Partial Onset Seizures In Patients One Month Of Age And Older With Epilepsy ( 1.1 ) Myoclonic Seizures In Patients 12 Years Of Age And Older With Juvenile Myoclonic Epilepsy ( 1.2 ) Primary Generalized Tonic-Clonic Seizures In Patients 6 Years Of Age And Older With Idiopathic Generalized Epilepsy ( 1.3 ) 1.1 Partial Onset Seizures Levetiracetam Is Indicated As Adjunctive Therapy In The Treatment Of Partial Onset Seizures In Adults And Children 1 Month Of Age And Older With Epilepsy. 1.2 Myoclonic Seizures In Patients With Juvenile Myoclonic Epilepsy Levetiracetam Is Indicated As Adjunctive Therapy In The Treatment Of Myoclonic Seizures In Adults And Adolescents 12 Years Of Age And Older With Juvenile Myoclonic Epilepsy. 1.3 Primary Generalized Tonic-Clonic Seizures Levetiracetam Is Indicated As Adjunctive Therapy In The Treatment Of Primary Generalized Tonic-Clonic Seizures In Adults And Children 6 Years Of Age And Older With Idiopathic Generalized Epilepsy.

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Levetiracetam LEVETIRACETAM ZINC1547851

Comments